Bruce Colin Henderson

PneumoWave Ltd. is a British company based on a proprietary digital technology and behavioral health platform that provides real-time physiological data via patient-centric digital biomarkers. The company is based in Motherwell, UK. The company's core focus is to prevent deaths and reduce hospital admissions from respiratory failure. PneumoWave aims to reduce deaths in patients at risk of accidental overdose by early and accurate detection of respiratory depression and facilitating rapid access to overdose reversal agents. The company's device is part of a wider remote digital behavioral health platform that aims to provide physicians and care teams with a range of validated digital technologies that will enable more effective and efficient assessment and remote management of patients. PneumoWave has the potential to drive optimal, life-saving outcomes for patients. The company was founded by Jonathan Guthrie, Alexander Adam, Bruce Colin Henderson. Bruce Colin Henderson has been the CEO since incorporation.

PneumoWave Ltd. is a British company based on a proprietary digital technology and behavioral health platform that provides real-time physiological data via patient-centric digital biomarkers. The company is based in Motherwell, UK. The company's core focus is to prevent deaths and reduce hospital admissions from respiratory failure. PneumoWave aims to reduce deaths in patients at risk of accidental overdose by early and accurate detection of respiratory depression and facilitating rapid access to overdose reversal agents. The company's device is part of a wider remote digital behavioral health platform that aims to provide physicians and care teams with a range of validated digital technologies that will enable more effective and efficient assessment and remote management of patients. PneumoWave has the potential to drive optimal, life-saving outcomes for patients. The company was founded by Jonathan Guthrie, Alexander Adam, Bruce Colin Henderson. Bruce Colin Henderson has been the CEO since incorporation.

PneumoWave Ltd. is a British company based on a proprietary digital technology and behavioral health platform that provides real-time physiological data via patient-centric digital biomarkers. The company is based in Motherwell, UK. The company's core focus is to prevent deaths and reduce hospital admissions from respiratory failure. PneumoWave aims to reduce deaths in patients at risk of accidental overdose by early and accurate detection of respiratory depression and facilitating rapid access to overdose reversal agents. The company's device is part of a wider remote digital behavioral health platform that aims to provide physicians and care teams with a range of validated digital technologies that will enable more effective and efficient assessment and remote management of patients. PneumoWave has the potential to drive optimal, life-saving outcomes for patients. The company was founded by Jonathan Guthrie, Alexander Adam, Bruce Colin Henderson. Bruce Colin Henderson has been the CEO since incorporation.

PneumoWave Ltd. is a British company based on a proprietary digital technology and behavioral health platform that provides real-time physiological data via patient-centric digital biomarkers. The company is based in Motherwell, UK. The company's core focus is to prevent deaths and reduce hospital admissions from respiratory failure. PneumoWave aims to reduce deaths in patients at risk of accidental overdose by early and accurate detection of respiratory depression and facilitating rapid access to overdose reversal agents. The company's device is part of a wider remote digital behavioral health platform that aims to provide physicians and care teams with a range of validated digital technologies that will enable more effective and efficient assessment and remote management of patients. PneumoWave has the potential to drive optimal, life-saving outcomes for patients. The company was founded by Jonathan Guthrie, Alexander Adam, Bruce Colin Henderson. Bruce Colin Henderson has been the CEO since incorporation.